Epidemiology and outcome of sepsis in adult patients with Streptococcus pneumoniae infection in a Norwegian county 1993–2011: an observational study by Åsa Askim et al.
RESEARCH ARTICLE Open Access
Epidemiology and outcome of sepsis in
adult patients with Streptococcus
pneumoniae infection in a Norwegian
county 1993–2011: an observational study
Åsa Askim1,2,10,11*, Arne Mehl3,4,10, Julie Paulsen3,4,10, Andrew T. DeWan8, Didrik F. Vestrheim9, Bjørn Olav Åsvold5,7,10,
Jan Kristian Damås3,6,10 and Erik Solligård1,2,10
Abstract
Background: Invasive pneumococcal disease (IPD) is responsible for significant mortality and morbidity worldwide.
There are however few longitudinal studies on the changes in case fatality rate of IPD in recent years. We carried
out a prospective observational study of patients with IPD in Nord Trøndelag county in Norway from 1993 to 2011
to study the clinical variables and disease outcome. The main outcome was all-cause mortality after 30 and 90 days.
Methods: Patients with positive blood cultures were registered prospectively by the microbiology laboratory and
clinical variables were registered retrospectively from patients’ hospital records. The severity of sepsis was assigned
according to the 2001 International Sepsis Definition Conference criteria. The association between mortality and
predictive factors was studied using a logistic regression model.
Results: The total number of patients was 414 with mean age of 67 years and 53 % were male. Comorbidity was
assessed by the Charlson Comorbidity Index (CCI). A CCI-score of 0 was registered in 144 patients (34.8 %), whereas
190 had a score of 1–2 (45.9 %) and 80 (19.3 %) had a score ≥3. 68.8 % of the patients received appropriate
antibiotics within the first 6 h. The 30-day mortality risk increased by age and was 3-fold higher for patients aged
≥80 years (24.9, 95 % CI 16.4–33.4 %) compared to patients aged <70 (8.0, 95 % CI 3.5–12.4 %). 110 patients,
(26.6 %) had severe sepsis and 37 (8.9 %) had septic shock. The 30 day all-cause mortality risk for those with sepsis
without organ failure was 5.4 % (95 % CI 2.7–8.0 %), 20.2 % (95 % CI 13.5–27.4 %) for those with severe sepsis and
35.0 % (95 % CI 21.6–49.0 %) for those with septic shock. The mortality risk did not differ between the first and the
second halves of the study period with a 30-day mortality risk of 13.5 % (95 % CI 7.9–19.2 %) for 1993–2002 versus
11.8 % (95 % CI 8.2–15.3 %) for 2003–2011.
Conclusion: IPD carries a high mortality despite early and appropriate antibiotics in most cases. We found no
substantial decrease in case fatality rate during the study period of 18 years. Older age and higher severity of
disease were important risk factors for death in IPD.
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Background
Streptococcus pneumonia colonizes the upper airway in
approximately 10 % of adults and is responsible for the
majority of episodes of community-acquired pneumonia
[1, 2]. It may penetrate beyond epithelial cells and cause
invasive disease and bacteremia [3]. Invasive pneumococ-
cal disease (IPD) and sepsis are responsible for substantial
morbidity and mortality worldwide with about 2 million
deaths each year [4]. The case fatality rate of IPD and
sepsis is 11–30 % in studies in Europe and the US [5]. The
incidence of IPD is highest in the <2 and >65 year age
groups and in the older population, chronic comorbid dis-
ease is a risk factor for acquiring IPD [2]. The 23-valent
pneumococcal polysaccharide vaccine (PPV23) has been
recommended to risk-groups and adults aged ≥65 years
since 1996. The uptake is limited, and has been estimated
to be about 15–30 % [6]. The 7-valent pneumococcal
conjugate vaccine (PCV7) was introduced in the child-
hood immunization program in July 2006, and was re-
placed by the 13-valent vaccine (PCV13) in 2011. Since
2009, the uptake has been about 92 % for the complete
immunization schedule [7].
The development of fatal pneumococcal sepsis depends
on a complex interplay between the host and the microbe
[8, 9]. Host factors such as diabetes, liver disease and
COPD are associated with increased case fatality rate
among immunocompetent patients. In the immunocom-
promised patients, HIV-infection, chronic renal failure
and malignant disease have been associated with increased
case fatality [10, 11]. Various guidelines have been devel-
oped to describe the optimal management of IPD and
sepsis, such as the Surviving sepsis campaign [12] and
guidelines for management of severe community acquired
pneumonia [13]. These have had an impact on early rec-
ognition and treatment of septic patients, for instance by
underscoring the importance of early antibiotic treatment
[14]. However, important determinants of poor outcome
of the disease remain to be identified to improve the man-
agement and treatment of IPD patients. We carried out a
prospective observational study of risk factors for 30 and
90-day mortality among patients with IPD and sepsis in
Nord-Trøndelag county, Norway from 1993 to 2011.
Methods
Setting and population
Nord-Trøndelag is a county in Central Norway with a
population of approximately 134 000. It has both coastal
and inland municipalities and consists of rural areas as
well as small cities, but lack big cities. It is served by two
community hospitals, Namsos Hospital and Levanger
Hospital. The closest tertiary referral hospital is St Olav’s
Hospital, Trondheim University Hospital. We included all
patients ≥16 years of age with IPD confirmed by growth
of S.pneumoniae in blood culture or cerebrospinal fluid at
Levanger Hospital between 1993 and 2011, and at Namsos
Hospital between 1999 and 2011. Residents of Nord-
Trøndelag with IPD detected at St Olav’s Hospital between
1993 and 2011 were also included if they participated in a
population survey (the HUNT-2 Survey) between
1995 and 1997 [15].
BACTEC 9240 (Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MD) was used for blood culture
testing until the beginning of 2010 and thereafter the
Bactec FX [16]. Spinal fluid samples were cultured on
chocolate plates incubated in an atmosphere of 5 % CO2
for 2–3 days. S. pneumoniae was identified by typical
colony morphology, microscopic morphology, and opto-
chin sensitivity. Antibiotic susceptibility testing and
screening for penicillin resistance (oxacillin 1 μg disk)
were performed by the disc-diffusion method (Oxoid,
UK). Penicillin MIC determination (E test, AB Biodisk,
Sweden) was performed in all pneumococcal isolates.
Antimicrobial susceptibility was categorized according
to breakpoints from EUCAST (www.eucast.org). Penicil-
lin non-susceptibility was categorized using the break-
point for meningitis cases (MIC >0.064 mg/l).
Serotyping
S. pneumoniae isolates from cases of IPD were forwarded
to the National Reference Laboratory for Pneumococci at
the Norwegian Institute of Public Health. Isolates were
confirmed as pneumococci, and serotyped by the Quel-
lung reaction using serotype-specific antisera (Statens
Seruminstitut, Copenhagen, Denmark) [17].
Patient characteristics
All patients with positive blood cultures were prospect-
ively registered and clinical information was extracted
retrospectively from the patients’ hospital records. All data
were collected using a standardized data retrieval form
assessing patients’ characteristics, comorbid conditions,
results of investigations and treatment. The data collection
was carried out by trained research nurses and all regis-
tered data was secondarily assessed by an infectious
disease consultant or the first author of the study. An epi-
sode of bloodstream infection was defined as the presence
of one or more microorganism(s) in blood culture along
with clinical evidence of infection. If a patient had more
than one episode of S. pneumoniae bacteremia during the
study period, only the first was included.
The setting of infection was classified as hospital-
acquired (HA), healthcare- associated (HCA) or
community-acquired (CA) as defined by Friedman et al.
[18]. Patients who were hospitalized for two or more
days during the 30 days prior to the infection were clas-
sified as having a HCA infection, in keeping with the
definition used by Siegman-Igra et al. [19]. The number
and severity of combined comorbid conditions were
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assessed according to the Charlson weighted Comorbid-
ity Index (CCI) [20]. Case fatality rate was measured as
all-cause mortality within day 30 and 90. By using the
11-digit unique identification number of all Norwegian
citizens, electronic hospital records in Norway are up-
dated with mortality data from the Norwegian popula-
tion registry so that mortality data after discharge from
hospital can be reliably assessed [21, 22].
Severity of disease
Severity of disease (sepsis without organ failure, severe
sepsis and septic shock) was determined according to
the 2001 International Sepsis Conference definition [23].
We defined sepsis as documented bloodstream infection
and two or more of the following: temperature ≥38.3 °C
or <36.0 °C, heart rate >90 beats/min, respiratory rate
>20/min or PaCo2 < 4.3 kPa or mechanical ventilation
due to acute respiratory failure, glucose >7.7 mmol/l in
the absence of diabetes, leucocytes >12 × 109/l or <4 ×
109/l, elevated CRP or procalcitonin, acute hypotension
(systolic BT <90 mmHg, MAP <70 mmHg or a fall of
≥40 mmHg), or need of fluid resuscitation (>20 ml/kg
over 24 h). The specific criteria for organ dysfunc-
tion used were the same as those outlined in the
2001 International Sepsis Conference definition [23].
Any changes in disease severity were registered. The
most severe deterioration of organ function was
noted and used to define whether the patient had
sepsis, severe sepsis or septic shock. For those who
did not show any evidence of deterioration during
the episode, the day of positive blood culture was
registered as the day with the most severe affection.
Severity of disease was also assessed by the Pitt
bacteremia score [24].
Focus of infection
Lower respiratory tract focus was diagnosed with clinical
signs of respiratory infection and positive radiologic
findings. Reported signs of infection along with focal
growth of the same microbe as in the blood culture was
taken as a confirmation of skin, soft tissue, joint or sur-
gical infection. Meningitis was diagnosed with clinical
signs and growth of the microbe in the cerebrospinal
fluid. Upper respiratory tract infection was defined as
otitis media or sinusitis. Otitis media was diagnosed as
inflammation and accumulation of infected fluid of the
middle ear and fever. Sinusitis was defined as inflamma-
tion of the sinuses, fever, pain in the face or headache
and the presence of thick nasal mucus. An abscess was
defined as a localized collection of pus in a tissue to-
gether with bacteremia. An unknown focus of infection
was assigned when none of the criteria for ascertaining a
focus were met.
Initial antibiotic treatment
Appropriateness of initial antibiotic therapy (AIAT) was
evaluated: initial therapy had to be given (1) intravenously
in correct doses and timely after the blood culture speci-
men was obtained (<6 h or >6 h), (2) with a regimen that
was active in vitro against the microbe(s) isolated from
blood culture(s).
Statistical analysis
Data was analyzed using SPSS for Windows (Version 21,
Armonk, NY: IBM Corp) and STATA version 13 (Stata
Corp LP, College Station, Texas). The associations be-
tween clinical characteristics and 30 and 90-day mortal-
ity were investigated using logistic regression analysis
where odds ratios (ORs) with 95 % confidence intervals
(CI) were estimated. In addition, we studied the associ-
ation between clinical characteristics and severe sepsis/
septic shock as an outcome, in order to identify groups
of patients particularly vulnerable to develop severe dis-
ease and need a higher level of follow-up and care. All
associations were estimated both unadjusted and ad-
justed for potential confounders, chosen based on prior
knowledge of factors that may influence both the expos-
ure variable under interest and the risk of the outcome
(death or sepsis severity). All adjusted analyses were ad-
justed for sex and age group (≤70, 70–79 and ≥80 years).
The association of the setting of infection, focus, sever-
ity, and time period were additionally adjusted for
comorbid conditions using three categories of the CCI
(0, 1–2 and ≥3). Adjusted 30- and 90-day mortality risks
and risk of severe sepsis/shock were estimated from the
logistic regression model by using the margins post-
estimation command in Stata. For ordinal variables, we
tested for linear trend across categories by using the cat-
egories as a continuous variable in the logistic regression
model.
Results
We identified 414 patients with IPD during the study
period. All met the sepsis criteria. The mean age was
67 years and 52.9 % were male. In 78.1 % of the patients,
the infection was community-acquired, 17.6 % of infec-
tions were healthcare-associated and 4.3 % were hospital-
acquired. The all-cause mortality rate was 12.3 % at
30 days and 16.7 % at 90 days (Table 1). A CCI-score of 0
was registered in 144 patients (34.8 %), whereas 1–2 in
190 (45.9 %) and ≥3 in 80 (19.3 %) of the patients
(Table 1).
The 30-day mortality risk increased by age (p for
trend <0.001). The 30-day mortality risk was 3 fold higher
for patients aged 80 years or older (24.9, 95 % CI 16.4–
33.4 %) compared to patients aged under 70, (8.0, 95 % CI
3.5–12.4 %) (Table 2). A positive association with age was
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also seen for the 90-day mortality risk (Additional file 1:
Table S1).
Females had lower 30-day mortality risk than males
8.9 % vs 15.4 % (OR 0.51 95 % CI 0.27–0.97) (Table 2).
This association was nearly unchanged but less precise
after adjusting for comorbid disease (OR 0.55 95 % CI
0.29–1.05) and after adjusting for severity of sepsis on
admission, time to antibiotics and place of acquisition
(OR 0.54 95 % CI 0.26–1.10). A similar gender associ-
ation was also seen for 90-day mortality risk. (Additional
file 1: Table S1).
The initial antibiotic treatment was mainly penicillin,
which is the standard empiric treatment for community-
acquired pneumonia in Norway or penicillin in combin-
ation with aminoglycoside, which is the standard empiric
treatment for severe community-acquired pneumonia or
sepsis of unknown origin period. Overall, 85.5 % re-
ceived antibiotics according to national guidelines [25,
26], 97.8 % of the pneumococcal isolates were sensitive
to penicillin. Of the 406 isolates, 397 were sensitive to
penicillin, seven were intermediate and two were resist-
ant. We did not have information about eight samples.
Within 6 h, 68.8% of the patients received antibiotic
treatment, 18.6 % received treatment after 6 h and data
on timing of treatment were lacking for 12.6 % of the
patients. Patients who received antibiotics before 6 h
had a 30-day mortality risk of 11.9 % (95 % CI 8.5–
15.3 %), which was similar to patients who received anti-
biotics after 6 h (13.2, 95 % CI 8.1–18.4 %) (Table 3).
With regard to severity of disease, 64.5 % of the pa-
tients had sepsis without organ failure, 26.6 % had severe
sepsis and 8.9 % had septic shock. In patients with sepsis
with no organ failure the 30- day mortality risk was
5.4 % (95 % CI 2.7–8.0 %), the 30-day mortality risk was
almost 4-fold higher for patients with severe sepsis (20.2,
95 % CI 13.5–27.4 %) and more than 6-fold higher for
patients with septic shock (35.0, 95 % CI 21.6–49.0 %)
(Table 3). A similar association was seen for 90-day mor-
tality risk (Additional file 1: Table S2).
An increase in mortality risk according to severity was
also observed for the Pitt bacteremia score, especially for
Table 1 Patient and infection characteristics
Characteristic N (%)












< 50 69 (16.7)
50–69 131 (31.6)
70–79 104 (25.1)
≥ 80 110 (26.6)
Comorbid conditions
Malignancy 90 (21.7)
Renal failure 24 (5.8)
Diabetes mellitus 51 (12.3)
Hypertension 98 (23.7)
Coronary heart disease 84 (20.3)
Heart failure 40 (9.7)
Chronic pulmonary disease 96 (23.2)
Cerebral ischemic disease 40 (9.7)
Charlson comorbidity index (CCI)
0 144 (34.8)
1–2 190 (45.9)
≥ 3 80 (19.3)
Severity of sepsis
Sepsis without organ failure 267 (64.5)
Severe sepsis 110 (26.6)





≥ 3 85 (20.6)
Focus of infection N (%)
Abdomen 4 (1.0)
Lower respiratory tract 344 (83.0)
Upper respiratory tract 11 (2.7)
Skin/soft tissue/abscess/myositis 13 (3.1)
Meningitis 26 (6.3)
Unknown 16 (3.9)





Treatment in Intensive Care Unit(ICU) 136 (32.9)
Treatment with vasopressors 40 (9.6)
Ventilator treatment 16 (3.9)
Penicillin-sensitive Streptococcus pneumoniae 397 (97.8)a
aWe had information about 406 isolates of S.pneumoniae
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patients with Pitt bacteremia score ≥3 (Table 3 and
Additional file 1: Table S2).
There was no convincing association between CCI-
score and 30-day mortality but patients with a CCI-score
≥3 had a twofold higher 90-day mortality risk (27.2, 95 %
CI 18.8–35.7 %) compared to patients with a CCI score of
0 (12.9, 95 % CI 6.3–19.5 %) (Additional file 1: Table S1).
With regard to individual comorbidities, hypertension was
associated with increased 30-day mortality risk (OR 2.35,
95 % CI 1.22–4.54) (Table 2). A similar result was ob-
served for 90-day mortality (Additional file 1: Table S1).
This study was carried out over a period of more than
18 years. The age, sex and comorbidity adjusted 30- day
mortality risk did not differ between the first (1993–2002)
and second (2003–2011) periods of the study (13.5, 95 %
CI 7.9–19.2 %) vs (11.8, 95 % CI 8.2–15.3 %) (Table 3).
The 90-day mortality risk tended to be higher in the first
than the second period (20.6, 95 % CI 14.2–27.0 %) vs
(14.9, 95 % CI 11.0–18.7 %) (Additional file 1: Table S2).
Patients with heart failure had the highest risk of
acquiring severe sepsis or septic shock (58.1, 95 % CI
33.4–73.5 %) and patients with renal failure had a risk of
53.5 % (95 % CI 33.4–73.5 %). The risk of acquiring
severe sepsis or septic shock was lower in the second
half of the study with an adjusted risk of 29.9 % (95 %
CI 24.5- 35.2 %) versus 47.3 % (95 % CI 38.9–55.7 %)
(Table 4).
Serotype-information was available in 373 patients
(90 %). Before introduction of the 7-valent pneumococcal
conjugate vaccine (PCV 7) in the childhood immunization
in 2006, the most frequent serotypes were 4, 14, 1, 9 and
3. In the period 2007 to 2011 the most frequent serotypes
were 7 F, 22 F, 4, 3 and 19A, of which only serotype 4 is
included in PCV 7 (Additional file 2: Figure S1–3).
Discussion
In our study, there were strong positive associations of
age and disease severity with case fatality rate in patients
with IPD and sepsis. We did not observe a reduction in
mortality risk over the time of our study.
IPD is a severe disease that predominantly occurs in
elderly people with comorbid disease [27]. The mortality
risk was higher in patients >80 years of age than in
younger patients. First, the clinical presentation of sepsis
in elderly patients may differ from younger patients.
Unspecific symptoms, like abdominal pain, confusion or
Table 2 30-day all-cause mortality in relation to patient characteristics prior to infection





Odds ratio 95 % CI p Mortality risk (%) 95 % CI
Age (years)
< 70 12 6.0 1 Reference 8.0 3.5–12.4
70–79 15 14.4 2.72 1.21–6.07 0.02 14.0 7.4–20.6
≥ 80 24 21.8 5.57 2.63–11.78 <0.001 24.9 16.4–33.4
p for trend <0.001
Sex
Male 33 15.1 1 Reference 15.4 10.8–20.1
Female 18 9.2 0.51 0.27–0.97 0.040 8.9 5.0–12.8
Charlson Comorbidity Index (CCI)
0 12 8.4 1 Reference 12.9 6.3–19.5
1–2 20 10.5 0.67 0.30–1.51 0.34 9.3 5.5–13.1
≥ 3 19 23.8 1.54 0.66–3.60 0.32 18.1 10.8–25.4
p for trend 0.11
Comorbidities a
Malignant disease 18 20.0 1.61 0.82–3.13 0.15 16.1 9.2–23.0
Renal failure 6 25.0 2.25 0.82–6.21 0.11 21.7 7.0–36.4
Diabetes mellitus 9 17.6 1.44 0.64–3.28 0.43 15.7 6.1–24.9
Hypertension 22 22.4 2.35 1.22–4.54 0.01 19.3 12.0–26.6
Coronary heart disease 16 19.0 1.05 0.52–2.11 0.75 12.6 6.7–18.6
Heart failure 6 15.0 0.62 0.23–1.62 0.35 8.7 1.9–15.4
Chronic pulmonary disease 10 10.4 0.73 0.34–1.55 0.49 10.0 4.3–15.8
Cerebral ischemic disease 7 17.5 1.03 0.40–2.50 0.93 12.4 6.7–18.6
aThose not having the condition were used as reference category
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specific organ symptoms like dyspnea, can delay the
sepsis diagnosis and initiation of therapy [28]. Indeed a
recent Norwegian study found that antimicrobial therapy
was less in compliance with current recommendations
and more delayed in elderly patients with sepsis [29].
Second, ageing of the immune system and impaired ef-
fect of vaccine also contribute to the mortality risk [27].
Also, elderly patients may not be admitted to the inten-
sive care unit due to high comorbidity burden or an end
of life care situation.
We assessed whether individual prior comorbid condi-
tions influenced the risk of acquiring severe sepsis or
septic shock and found this risk was highest for patients
with heart failure and renal failure. This is probably
because of reduced residual capacity to meet the
hemodynamic burden associated with severe sepsis
[27, 30]. Interestingly, we found that females had lower
mortality risk than males for both 30-day and 90-day mor-
tality. Males had a higher comorbidity burden than
females, but adjusting for comorbid disease did not
change the risk estimate, neither did adjusting for severity
on admission, place of acquisition or time for antibiotic
treatment. Differences in alcohol and smoking habits may
have influenced the mortality risk but we could not exam-
ine that possibility [31, 32].
A high proportion of the patients in our study received
antibiotics according to guidelines and within the first
6 h after admission in the hospital or in the hospital
within 6 h after suspected invasive infection and sepsis.
There was no significant reduction in mortality when
comparing whether the patients received antibiotics
within 6 h or after 6 h. Confounding by indication is a
complicating factor when assessing the effect of anti-
biotic treatment and outcome. It is possible that those
with more severe illness received antibiotic treatment
earlier. We adjusted for age, sex, comorbid disease bur-
den and severity but there may still be unadjusted differ-
ences between the groups. In addition, it is likely that
there were variations in time from how long the patients
had suffered from the infection prior to admission since
almost 80 % of the patients had community- acquired
infection.
As expected, we saw a change in the serotype pattern
before and after 2006. The three most frequent serotypes
after 2006 were 7 F, 22 F, and 3. A metaanalysis from
2010 found that serotypes 3,6A, 6B, 9 N and 19 F were
Table 3 30 day all-cause mortality in relation to disease acquisition, severity, focus and time period




Age-, sex- and comorbidity-adjusteda
Odds ratio 95 % CI p Mortality risk (%) 95 % CI
Place of acquisition
Community acquired 34 10.6 1 Reference 10.9 7.6–14.3
Health-care associated 12 17.0 1.58 0.65–3.20 0.35 14.7 6.9–22.4
Hospital acquired 5 27.8 3.13 0.92–10.43 0.07 25.2 6.7–43.9
Severity
Sepsis without organ failure 14 5.2 1 Reference 5.4 2.7–8.02
Severe sepsis 23 21.0 5.19 2.44–11.10 <0.001 20.2 13.5–27.4
Septic shock 14 37.8 13.58 5.32–34.60 <0.001 35.0 21.6–49.0
p for trend <0.001
Pitt bacteremia score
0 12 9.5 Reference 9.4 4.5–14.3
1 7 5.4 0.47 0.17–1.28 0.14 4.9 1.4–8.3
2 8 11.1 1.45 0.53–3.94 0.47 12.7 4.9–20.5
≥3 24 28.2 5.10 2.12–11.65 <0.001 29.8 20.7–39.0
p for trend <0.001
Time period
1993–2002 17 12.7 1 Reference 13.5 7.9–19.2
2003–2011 34 12.1 0.77 0.43–1.61 0.59 11.8 8.2–15.3
Time to antibioticsb
<6 hours 33 14.1 1 Reference 11.9 8.5–15.3
>6 hours 18 11.5 1.17 0.58–2.34 0.65 13.2 8.1–18.4
aAdjusted for Charlson Comorbidity Index: 0, 1–2 and ≥3 bAlso adjusted for severity
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associated with increased risk of death and these had
high carrier prevalence, low invasiveness and were en-
capsulated in vitro [33]. We did not have the statistical
power to examine differences in mortality between dif-
ferent serotypes. Following the introduction of PCV7 in
the childhood immunization program in 2006 the inci-
dence of IPD declined in all age groups as a result of
indirect effect [17]. This decline continued after the
switch to PCV13 in 2011 [7]. PCV13 has been licensed
for prevention of IPD in all age-groups, and in 2013 the
Norwegian Institute of Public Health updated the
recommendations for use of pneumococcal vaccines to
elderly and risk-groups with a recommendation to use
PCV13 in addition to PPV23 for persons with a very
high risk for IPD [34]. However, as the impact of PCV13
in the childhood immunization program continues to
reduce circulation of PCV13 serotypes, the preventive
potential of PCV13 given to adults and risk-groups is
reduced over time [6].
We did not demonstrate any reduced mortality risk
over the time of our study, but the risk of acquiring
severe sepsis was significantly decreased in the later
period. This may be for several reasons such as intro-
duction of the pneumococcal vaccine in the childhood
vaccination program which has shown to influence other
age groups in the society [1] and improved patient man-
agement as part of a continuing awareness of severe infec-
tions and sepsis [35].
Table 4 Proportion of severe sepsis/septic shock according to prior patient characteristics and infection-related characteristics
Characteristic No with severe sepsis
or septic shock
Severe sepsis or septic
shock in category (%)
Age-, sex- and comorbiditya-adjusted
Odds ratio 95 % CI p Risk of severe sepsis
or septic shock (%)
95 % CI
Age (years)
<70 73 36.5 1 Reference 35.0 28.7–42.0
70–79 33 31.7 0.81 0.48–1.37 0.44 30.8 22.0–39.8
≥80 41 37.2 1.24 0.75–2.10 0.39 40.7 30.8–50.5
p for trend 0.49
Sex
Male 82 37.4 1 Reference 37.6 31.2–44.0
Female 65 33.3 0.88 0.57–1.34 0.54 33.1 26.5–39.8
Charlson ComorbidityIndex (CCI)
0 46 31.9 1 Reference 33.0 24.7–41.2
1–2 70 36.8 1.10 0.64–1.91 0.73 36.5 29.5–43.3
≥3 31 38.7 1.29 0.72–2.29 0.39 37.7 26.8–48.5
p for trend 0.37
Comorbiditiesa
Malignant disease 33 36.7 0.98 0.59–1.61 0.94 35.1 25.2–45.1
Renal failure 16 66.7 2.20 0.95–5.11 0.07 53.5 33.4–73.5
Diabetes mellitus 14 27,4 0.62 0.32–1.21 0.16 26..7 14.6–38.7
Hypertension 38 38.7 1.17 0.71–1.91 0.54 38.2 28.2–48.1
Coronary heart disease 37 30.3 0.66 0.38–1.15 0.14 28.3 18.4–38.2
Heart failure 23 57.5 2.82 1.39–5.74 0.004 58.1 42.0–74.1
Chronic pulmonary disease 39 40.6 1.34 0.83–2.15 0.23 40.7 30.8–50.5
Cerebral ischemic disease 12 30.0 0.69 0.33–1.43 0.32 28.3 14.4–42.2
Place of acquisition
Community acquired 112 34.7 1 Reference 34.6 29.6–40.0
Health-care associated 25 34.2 0.95 0.54–1.68 0.87 33.6 23.0–45.7
Hospital acquired 10 55.6 2.37 0.88–6.39 0.09 55.7 32.5–76.6
Time periode
1993–2002 63 47.0 1 Reference 47.3 38.9–55.7
2003–2011 84 30.0 0.47 0.30–0.72 0.01 29.9 24.5–35.2
aThe association of age, sex, CCI and individual underlying comorbidities with the risk of severe sepsis or septic shock are not adjusted for comorbidity
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All patients had verified bacteremia and the blood
culture were prospectively registered by the microbiol-
ogy laboratory, which ensures a broad inclusion of all
affected patients. Sepsis was diagnosed in IPD-patients
independent of primary focus, microbiological etiology
and host factors. This study has, however, some limita-
tions. The clinical data were collected from hospital
records at a later date which is inferior to prospective
clinical assessment but detailed data were available on
the majority of the patients. It is a strength of our study
that all IPD cases were confirmed by growth in blood
culture or, in a few cases, in cerebrospinal fluid. How-
ever, it is also possible to suffer from IPD without having
verified bacteremia or growth in the cerebrospinal fluid,
for example, if antibiotic treatment was given prior to
blood sampling, and we could not identify and include
such patients. The study was carried out only in one re-
gion in Norway and may not be generalizable, particu-
larly outside Scandinavia. Regrettably, we did not have
information on vaccine status, which would have been
an interesting aspect to assess in this population.
Conclusions
In conclusion, we found that older age and higher severity
of disease were important risk factors for death among
patients with IPD and sepsis. We found no substantial
decrease in case fatality rate during the study period. The
study contributes to the understanding of IPD and sepsis
in Norway.
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